Sunitinib Eugia: Uses, Dosage & Side Effects
A multi-targeted protein kinase inhibitor used to treat gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma, and pancreatic neuroendocrine tumors
Sunitinib Eugia contains the active substance sunitinib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks several proteins involved in cancer cell growth and the formation of new blood vessels that supply tumors. It is approved for the treatment of gastrointestinal stromal tumors (GIST) after failure of imatinib, metastatic renal cell carcinoma (advanced kidney cancer), and progressive pancreatic neuroendocrine tumors. Sunitinib Eugia is a generic version of the original brand SUTENT and is taken orally as a hard capsule, most commonly initiated at the 12.5 mg strength for dose adjustments. This medication requires a prescription and must be used under close oncology supervision due to its significant side effect profile.
Quick Facts: Sunitinib Eugia
Key Takeaways
- Sunitinib Eugia is a multi-targeted tyrosine kinase inhibitor that blocks proteins involved in tumor growth and angiogenesis, including VEGFR, PDGFR, KIT, FLT3, CSF-1R, and RET receptors.
- It is approved for three cancer types: GIST (after imatinib failure), metastatic renal cell carcinoma, and progressive or unresectable pancreatic neuroendocrine tumors (pNET).
- The 12.5 mg hard capsule is the lowest available strength and is used for the minimum recommended dose, for fine-tuned dose reductions in 12.5 mg increments, and for managing side effects or drug interactions.
- Regular monitoring of blood pressure, thyroid function, blood counts, and liver function is essential throughout treatment, as sunitinib can cause significant cardiovascular, endocrine, and hematologic side effects.
- Strong CYP3A4 inhibitors (ketoconazole, grapefruit juice) and inducers (rifampicin, St. John’s Wort) can significantly alter sunitinib blood levels and should be avoided or managed with dose adjustments.
- Women of childbearing potential must use reliable contraception during treatment; sunitinib should not be used during pregnancy or breastfeeding due to potential harm to the developing child.
What Is Sunitinib Eugia and What Is It Used For?
Sunitinib Eugia contains the active substance sunitinib, which belongs to a class of anticancer drugs known as protein kinase inhibitors (also called tyrosine kinase inhibitors or TKIs). These drugs work by blocking the activity of specific enzymes (protein kinases) that play a crucial role in the signaling pathways that regulate cell growth, proliferation, and the formation of new blood vessels (angiogenesis). By inhibiting these pathways, sunitinib effectively starves tumors of their blood supply while directly interfering with the signals that tell cancer cells to grow and divide.
Unlike many targeted therapies that block a single target, sunitinib is a multi-targeted inhibitor. It simultaneously blocks several different receptor tyrosine kinases, including platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), the stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). This broad spectrum of activity makes sunitinib effective against multiple types of cancer that depend on these signaling pathways for their growth and survival.
Sunitinib Eugia is approved by the European Medicines Agency (EMA) and regulatory authorities worldwide for the treatment of the following cancers:
- Gastrointestinal Stromal Tumors (GIST): GIST is a type of cancer that develops in the wall of the stomach or intestines. Sunitinib Eugia is used when imatinib (another targeted cancer drug that is typically the first-line treatment for GIST) has stopped working or when the patient cannot tolerate imatinib. The approval was based on a pivotal phase III trial that demonstrated a significant improvement in time to tumor progression compared with placebo in imatinib-resistant or imatinib-intolerant GIST patients.
- Metastatic Renal Cell Carcinoma (MRCC): This is a type of kidney cancer that has spread to other parts of the body. Sunitinib is used as a treatment for advanced renal cell carcinoma and has been one of the standard-of-care options in this setting. The landmark phase III trial comparing sunitinib with interferon-alpha demonstrated superior progression-free survival and objective response rates, establishing sunitinib as a first-line treatment option for metastatic clear cell renal cell carcinoma.
- Pancreatic Neuroendocrine Tumors (pNET): These are tumors that arise from the hormone-producing cells of the pancreas. Sunitinib Eugia is used when the tumor is progressing (getting worse) or cannot be removed by surgery. The phase III trial in advanced pNET demonstrated a doubling of progression-free survival compared with placebo, leading to regulatory approval in this indication.
Sunitinib Eugia is a generic version of the original brand SUTENT (manufactured by Pfizer). As a generic medicine, it has been demonstrated to be bioequivalent to the reference product, meaning it contains the same active substance in the same amounts and works in the same way in the body. Regulatory authorities approve generic versions of sunitinib only after rigorous evaluation of pharmaceutical quality, bioequivalence, and manufacturing standards. Other generic versions of sunitinib on the international market include Sunitinib Accord, Sunitinib Zentiva, Sunitinib Sandoz, Sunitinib STADA, Sunitinib Teva, Sunitinib Glenmark, Sunitinib Bluefish, and Sunitinib Avansor.
Sunitinib’s ability to block multiple receptor tyrosine kinases simultaneously is a key advantage. By targeting both tumor cell growth signals (through KIT, PDGFR, FLT3, and RET) and the blood vessel formation process (through VEGFR1/2/3), sunitinib attacks the tumor from two directions: directly slowing cancer cell proliferation while also cutting off the blood supply that the tumor needs to grow. However, this broad activity also contributes to its side effect profile, as some of these targets are important in normal tissues as well.
About the 12.5 mg Hard Capsule
The 12.5 mg strength represents the lowest available capsule and serves several important clinical purposes. It is used in patients who require the minimum recommended dose of sunitinib, in patients who have required stepwise dose reductions due to intolerable side effects, in patients being co-treated with strong CYP3A4 inhibitors where total daily dose must be lowered, and in patients with significant hepatic impairment. Because sunitinib dose adjustments are made in 12.5 mg increments (from 50 mg to 37.5 mg to 25 mg), the 12.5 mg capsule is an essential tool for individualized dosing throughout the course of treatment.
What Should You Know Before Taking Sunitinib Eugia?
Before starting treatment with Sunitinib Eugia, a detailed medical review is required. Sunitinib is a potent anticancer medicine that affects many physiological systems, including the cardiovascular, endocrine, hepatic, renal, hematologic, and integumentary systems. A thorough understanding of your medical history allows the oncology team to identify risks, plan appropriate monitoring, and adjust the treatment plan to minimize harm while maintaining efficacy against the cancer.
Contraindications
The primary contraindication for Sunitinib Eugia is hypersensitivity (allergy) to sunitinib or any of the other ingredients in the capsule. If you have previously experienced an allergic reaction to sunitinib-containing products, you must not take this medication. The inactive ingredients include microcrystalline cellulose, mannitol (E421), croscarmellose sodium, povidone (E1201), and magnesium stearate, along with gelatin and various iron oxides in the capsule shell.
There are no absolute contraindications beyond hypersensitivity, but there are several clinical situations in which sunitinib should not be started or should be temporarily withheld. These include uncontrolled hypertension, severe active bleeding, current severe congestive heart failure, recent myocardial infarction or stroke, and the immediate perioperative period. In each of these cases, sunitinib should only be introduced or reintroduced once the underlying condition is stabilized and the benefit-risk balance is acceptable.
Warnings and Precautions
Before starting Sunitinib Eugia, your doctor needs to be aware of all your current and past medical conditions. Sunitinib has a broad range of potential effects on the body, and certain pre-existing conditions may require closer monitoring, dose adjustments, or may make sunitinib unsuitable for you. Discuss the following with your healthcare provider:
Sunitinib can cause serious cardiovascular events including heart failure, cardiomyopathy, reduced left ventricular ejection fraction, QT prolongation, and myocardial infarction. Tell your doctor immediately if you experience extreme tiredness, shortness of breath, swollen feet and ankles, chest pain, dizziness, fainting, or abnormal heartbeats during treatment.
- High blood pressure: Sunitinib frequently raises blood pressure. Your doctor should monitor blood pressure regularly throughout treatment and may prescribe antihypertensive medication if needed. In some cases, dose reduction or temporary interruption of sunitinib may be necessary.
- Blood disorders: Treatment with sunitinib can increase the risk of bleeding or change the number of blood cells, potentially causing anemia or affecting the blood’s ability to clot. If you take blood thinners such as warfarin or acenocoumarol, your bleeding risk may be further increased. Report any unusual bleeding to your doctor.
- Heart problems: Sunitinib can cause heart failure, cardiomyopathy, and abnormal heart rhythms (arrhythmias). Your doctor may perform electrocardiograms (ECG) and echocardiograms to monitor heart function. Report any symptoms of tiredness, breathlessness, swelling, dizziness, fainting, or palpitations immediately.
- Blood clots: Venous and arterial thromboembolic events, including stroke, heart attack, and pulmonary embolism, have been reported. Seek immediate medical attention if you experience chest pain, arm/back/neck/jaw pain, shortness of breath, numbness or weakness on one side of the body, difficulty speaking, or severe headache.
- Aneurysms: Sunitinib may increase the risk of aneurysms (enlargement and weakening of blood vessel walls) or arterial dissections (tears in blood vessel walls). Tell your doctor if you have a history of these conditions.
- Thrombotic microangiopathy (TMA): Damage to the smallest blood vessels has been reported. Report symptoms of fever, fatigue, bruising, bleeding, swelling, confusion, vision loss, or seizures to your doctor.
- Thyroid disorders: Sunitinib commonly causes hypothyroidism (underactive thyroid). Thyroid function should be tested before and regularly during treatment. Symptoms include increased tiredness, feeling colder than usual, or a deeper voice. Thyroid hormone replacement may be needed.
- Pancreatic and gallbladder problems: Pancreatitis and cholecystitis (gallbladder inflammation) have been reported. Tell your doctor about any abdominal pain, nausea, vomiting, or fever.
- Liver problems: Hepatotoxicity, including liver failure, has occurred. Your doctor should monitor liver function with blood tests before and during treatment. Report itching, yellowing of the eyes or skin, dark urine, or pain in the upper right abdomen.
- Kidney problems: Your doctor will monitor kidney function throughout treatment. Cases of proteinuria and nephrotic syndrome have been reported.
- Surgery: Sunitinib can impair wound healing. Treatment is usually stopped before planned surgery. Your doctor will determine when to restart, usually only after the surgical wound is fully healed.
- Jaw problems (osteonecrosis): If you experience pain in the mouth, teeth, or jaw, swelling, numbness, or loose teeth, contact your doctor and dentist immediately. This is especially important if you are receiving or have received intravenous bisphosphonates.
- Skin reactions: Serious skin conditions including pyoderma gangrenosum (painful skin ulcers), necrotizing fasciitis (life-threatening soft tissue infection), Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have been reported. Seek immediate medical attention if you develop red, target-like patches, widespread blistering, or signs of skin infection.
- Seizures: Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported. Contact your doctor if you experience high blood pressure, headache, or vision loss.
- Diabetes: Blood sugar levels should be monitored regularly in patients with diabetes, as dose adjustments of diabetes medications may be necessary. Hypoglycemia (low blood sugar) has been reported.
Recommended Monitoring During Treatment
Due to the wide range of potential organ toxicities, patients on sunitinib require a structured monitoring program. The typical monitoring schedule before and during treatment includes baseline and periodic assessment of blood pressure, complete blood count (CBC) including platelets, comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin) and kidney function (creatinine, urea), thyroid-stimulating hormone (TSH), urinalysis for proteinuria, electrocardiogram (ECG) in patients at risk of QT prolongation, and echocardiography in patients with pre-existing cardiac disease or during treatment if cardiac symptoms develop. Frequency of monitoring is usually greatest during the first several cycles and can then be individualized based on the patient’s clinical course.
Children and Adolescents
Sunitinib Eugia is not recommended for use in persons under 18 years of age. The safety and efficacy of sunitinib have not been established in the pediatric population, and there are insufficient data to support its use in children and adolescents. Specific concerns about growth plate abnormalities have been raised based on animal studies, and any pediatric use of sunitinib should only occur within the context of a clinical trial.
Pregnancy and Breastfeeding
Sunitinib Eugia should not be used during pregnancy unless clearly necessary. Women of childbearing potential must use a reliable method of contraception during treatment and for at least four weeks after the last dose. Do not breastfeed while taking sunitinib or for at least four weeks after the last dose. Animal studies have shown potential harm to the developing fetus, including embryo-fetal lethality and teratogenicity. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medicine.
Sunitinib may impair fertility in both men and women. Men of reproductive potential should also use effective contraception during treatment, and both men and women who wish to have children in the future should discuss fertility preservation options (such as sperm banking or oocyte cryopreservation) with their oncology team before starting therapy whenever feasible.
Driving and Operating Machinery
If you experience dizziness or unusual tiredness while taking sunitinib, exercise caution when driving or operating machinery. These are common side effects that may impair your ability to perform these activities safely. Visual disturbances and fainting have also been reported and may affect the ability to drive or use heavy equipment safely.
Sodium Content
Sunitinib Eugia contains less than 1 mmol (23 mg) sodium (from croscarmellose sodium) per capsule and is therefore considered essentially sodium-free. This is relevant for patients on a strictly controlled sodium diet, for example those with advanced heart failure or chronic kidney disease requiring dietary sodium restriction.
How Does Sunitinib Eugia Interact with Other Drugs?
Sunitinib is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. This means that other drugs that affect CYP3A4 activity can significantly alter sunitinib blood levels, potentially increasing toxicity or reducing effectiveness. It is critical to inform your doctor and pharmacist about all medications, supplements, and herbal products you are taking before starting sunitinib and any time a new medication is added during treatment.
Major Interactions (CYP3A4 Inhibitors – Increase Sunitinib Levels)
The following drugs inhibit CYP3A4 and may increase the concentration of sunitinib in your blood, potentially leading to increased side effects. Your doctor may need to reduce the sunitinib dose if co-administration cannot be avoided. In many cases, alternative medications with a lower risk of CYP3A4 inhibition can be used instead:
| Drug | Drug Class | Clinical Significance |
|---|---|---|
| Ketoconazole | Antifungal | Strong CYP3A4 inhibitor; can significantly increase sunitinib exposure |
| Itraconazole | Antifungal | Strong CYP3A4 inhibitor; dose reduction of sunitinib may be needed |
| Voriconazole / Posaconazole | Antifungal | Strong CYP3A4 inhibitors; avoid or consider dose reduction |
| Ritonavir | HIV Protease Inhibitor | Strong CYP3A4 inhibitor; significant interaction expected |
| Erythromycin | Macrolide Antibiotic | Moderate CYP3A4 inhibitor; may increase sunitinib levels |
| Clarithromycin | Macrolide Antibiotic | Strong CYP3A4 inhibitor; monitor for increased toxicity |
| Diltiazem / Verapamil | Calcium Channel Blocker | Moderate CYP3A4 inhibitors; may modestly increase sunitinib levels |
| Grapefruit juice | Food interaction | CYP3A4 inhibitor; must be avoided during treatment |
Major Interactions (CYP3A4 Inducers – Decrease Sunitinib Levels)
The following drugs induce CYP3A4 and may decrease the concentration of sunitinib in your blood, potentially reducing its anticancer effectiveness. Your doctor may need to increase the sunitinib dose if co-administration cannot be avoided, or ideally substitute an alternative medication that does not induce CYP3A4:
| Drug | Drug Class | Clinical Significance |
|---|---|---|
| Rifampicin | Antibiotic (Tuberculosis) | Strong CYP3A4 inducer; can significantly reduce sunitinib exposure |
| Rifabutin | Antimycobacterial | Moderate to strong CYP3A4 inducer; monitor efficacy |
| Phenytoin | Antiepileptic | Strong CYP3A4 inducer; may reduce sunitinib efficacy |
| Carbamazepine | Antiepileptic | Strong CYP3A4 inducer; may reduce sunitinib efficacy |
| Phenobarbital | Antiepileptic / Barbiturate | Strong CYP3A4 inducer; avoid if possible |
| Dexamethasone | Corticosteroid | Moderate CYP3A4 inducer; monitor sunitinib effectiveness |
| St. John’s Wort (Hypericum perforatum) | Herbal supplement | Strong CYP3A4 inducer; must not be taken with sunitinib |
Additional Interaction Considerations
Beyond CYP3A4-mediated interactions, sunitinib may also interact with anticoagulants (blood thinners) such as warfarin and acenocoumarol, increasing the risk of bleeding. If you are taking anticoagulants, your doctor will monitor you closely for signs of bleeding throughout your treatment, and more frequent international normalized ratio (INR) checks may be required when sunitinib is started, stopped, or dose-adjusted.
Sunitinib can cause QT prolongation, and caution is advised when used with other medications known to prolong the QT interval, such as certain antiarrhythmics (amiodarone, sotalol), antipsychotics (haloperidol, quetiapine), antidepressants (citalopram, escitalopram), and antibiotics (moxifloxacin, levofloxacin). An ECG may be required before and during treatment in patients taking multiple QT-prolonging drugs.
Always inform your doctor and pharmacist about all medicines you are taking, including over-the-counter medications, vitamins, and herbal supplements. Even commonly used over-the-counter products such as antacids and certain pain relievers can interact with cancer therapies and should be discussed before use.
What Is the Correct Dosage of Sunitinib Eugia?
Always take Sunitinib Eugia exactly as your doctor has told you. The dosage depends on the type of cancer being treated, and your doctor may adjust the dose based on how well you tolerate the medication and how your cancer responds to treatment. Available capsule strengths (12.5 mg, 25 mg, 37.5 mg, and 50 mg) allow for flexible dose adjustments in 12.5 mg increments; the 12.5 mg hard capsule is the lowest individual strength and is fundamental to individualized dosing.
Adults
GIST and Metastatic Renal Cell Carcinoma (MRCC)
The recommended starting dose is 50 mg taken orally once daily for 28 consecutive days (4 weeks), followed by a 14-day (2-week) rest period without medication. This constitutes one complete 6-week treatment cycle (“Schedule 4/2”). Your doctor will continue treatment cycles for as long as the cancer is responding and you are tolerating the medication. Dose reductions are made in 12.5 mg increments; the minimum recommended dose is 25 mg per day.
Pancreatic Neuroendocrine Tumors (pNET)
The recommended starting dose is 37.5 mg taken orally once daily on a continuous daily dosing schedule (no scheduled rest period). Dose adjustments may be made based on individual patient safety and tolerability. The dose may be increased to a maximum of 50 mg daily or decreased to a minimum of 25 mg daily in 12.5 mg steps.
Sunitinib Eugia capsules may be taken with or without food. Swallow the capsules whole with a glass of water. Do not open, crush, or chew the capsules. Try to take your dose at approximately the same time each day to maintain consistent blood levels. If you vomit shortly after taking a capsule, do not take a replacement dose – take the next dose at the usual time and inform your doctor if vomiting is recurrent.
Children and Adolescents
Sunitinib Eugia is not recommended for persons under 18 years of age. There are insufficient data on safety and efficacy in the pediatric population, and concerns exist regarding potential effects on bone growth and sexual maturation based on animal studies. Any pediatric use should occur only within the framework of a supervised clinical trial at a specialized oncology center.
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients may be more susceptible to certain side effects such as fatigue, cardiovascular events, and dehydration from diarrhea, and careful monitoring is recommended. Your doctor will determine the appropriate dose based on your overall health status, renal function, and ability to tolerate the medication.
Patients with Kidney or Liver Problems
For patients with mild to moderate kidney impairment, no initial dose adjustment is required, but close monitoring is advised. For patients on hemodialysis or with severe renal impairment, limited data are available and treatment should be initiated cautiously under specialist supervision. For patients with mild to moderate hepatic impairment (Child-Pugh A or B), no initial dose adjustment is required; for patients with severe hepatic impairment (Child-Pugh C), sunitinib has not been studied and its use is not recommended.
Dose Adjustments
Your doctor may increase or decrease your dose depending on how well you tolerate treatment. Dose modifications are typically made in 12.5 mg steps. Common reasons for dose reduction include severe side effects such as significant blood pressure elevation, severe fatigue, serious blood count changes, hand-foot skin reaction, or significant elevations of liver enzymes. If side effects become severe, your doctor may temporarily stop treatment and restart at a lower dose once the side effects have resolved or improved.
For patients taking concurrent strong CYP3A4 inhibitors, a dose reduction to a minimum of 37.5 mg daily (for GIST/MRCC) or 25 mg daily (for pNET) should be considered. For patients taking concurrent strong CYP3A4 inducers, a dose increase to a maximum of 87.5 mg daily (for GIST/MRCC) or 62.5 mg daily (for pNET) may be considered under careful clinical and laboratory monitoring.
| Patient Group | Starting Dose | Schedule | Typical Adjustment Range |
|---|---|---|---|
| Adults with GIST or MRCC | 50 mg once daily | 4 weeks on, 2 weeks off | 25–50 mg (12.5 mg steps) |
| Adults with pNET | 37.5 mg once daily | Continuous daily | 25–50 mg (12.5 mg steps) |
| On strong CYP3A4 inhibitor | Reduce by 12.5 mg | As per indication | Minimum 25–37.5 mg daily |
| On strong CYP3A4 inducer | Consider increase by 12.5 mg | As per indication | Up to 87.5 mg (GIST/MRCC) or 62.5 mg (pNET) |
| Severe hepatic impairment (Child-Pugh C) | Not recommended | – | Use not studied |
| Children < 18 years | Not recommended outside trials | – | Insufficient data |
Missed Dose
If you miss a dose of Sunitinib Eugia, do not take a double dose to make up for the missed one. Simply take your next scheduled dose at the usual time. Taking a double dose could increase the risk of side effects. If you are unsure about what to do, contact your doctor or pharmacist for advice, and keep a simple dosing diary if you find it difficult to remember whether you have taken your daily dose.
Overdose
If you accidentally take more capsules than prescribed, contact your doctor, hospital emergency department, or local poison information center immediately. You may need medical observation in a hospital setting, including electrocardiographic monitoring and blood counts. There is no specific antidote for sunitinib overdose, and treatment is supportive. Symptoms of overdose may include an intensification of known side effects such as severe nausea and vomiting, extreme fatigue, bleeding, and changes in blood counts.
What Are the Side Effects of Sunitinib Eugia?
Sunitinib has a broad range of potential side effects due to its multi-targeted mechanism of action. Many side effects are manageable with supportive care and dose adjustments. It is important to report all new symptoms to your healthcare team so they can be addressed promptly. Some side effects require immediate medical attention and may require dose reduction, temporary interruption, or permanent discontinuation of treatment.
Contact your doctor immediately if you experience: extreme tiredness, breathlessness, or swollen feet/ankles (heart problems); cough, chest pain, sudden shortness of breath, or coughing up blood (pulmonary embolism); changes in urination (kidney problems); severe or unusual bleeding; severe abdominal pain with fever (bowel perforation or pancreatitis); or widespread skin blistering or peeling.
Very Common
May affect more than 1 in 10 people
- Decreased platelet, red blood cell, and/or white blood cell counts (neutropenia)
- Shortness of breath
- High blood pressure (hypertension)
- Extreme tiredness, fatigue, weakness
- Swelling due to fluid retention under the skin and around the eyes
- Mouth pain/irritation, mouth sores, dry mouth, taste disturbance
- Nausea, vomiting, diarrhea, constipation
- Abdominal pain/swelling, decreased appetite
- Hypothyroidism (underactive thyroid)
- Dizziness, headache
- Nosebleeds, cough
- Back pain, joint pain, pain in arms and legs
- Yellowing or discoloration of skin, increased skin pigmentation
- Hair color change, hand-foot skin reaction, rash, dry skin
- Fever, difficulty sleeping
Common
May affect up to 1 in 10 people
- Blood clots in blood vessels (venous thromboembolism)
- Reduced blood supply to the heart (coronary artery disease)
- Chest pain, decreased cardiac output
- Fluid around the lungs (pleural effusion)
- Infections, sepsis (life-threatening blood infection)
- Low blood sugar (see warnings section)
- Protein in urine (proteinuria), flu-like symptoms
- Abnormal blood tests (liver and pancreatic enzymes), elevated uric acid
- Hemorrhoids, rectal pain, bleeding gums, difficulty swallowing
- Heartburn, increased gas, weight loss
- Muscle and skeletal pain, muscle weakness, muscle cramps
- Nasal dryness, nasal congestion, increased tearing
- Skin itching, skin peeling, blisters, acne, nail discoloration, hair loss
- Numbness or tingling in hands and feet (peripheral neuropathy)
- Dehydration, hot flushes, discolored urine
- Depression, chills
Uncommon
May affect up to 1 in 100 people
- Necrotizing fasciitis (life-threatening soft tissue infection)
- Stroke, heart attack
- Changes in heart’s electrical activity, abnormal heart rhythm, QT prolongation
- Fluid around the heart (pericardial effusion)
- Liver failure
- Pancreatitis (inflammation of the pancreas)
- Bowel perforation (tumor breakdown leading to a hole in the intestine)
- Gallbladder inflammation (cholecystitis), with or without gallstones
- Fistula (abnormal channel between body cavities or to the skin)
- Jaw osteonecrosis (bone damage in the jaw)
- Hyperthyroidism (overactive thyroid)
- Impaired wound healing after surgery
- Elevated creatine phosphokinase (muscle enzyme)
- Severe allergic reactions including anaphylaxis
- Colitis (inflammation of the colon)
Rare
May affect up to 1 in 1,000 people
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
- Tumor lysis syndrome (TLS) – metabolic complications from rapid cancer cell breakdown
- Rhabdomyolysis (abnormal muscle tissue breakdown that can lead to kidney damage)
- Reversible posterior leukoencephalopathy syndrome (RPLS) – brain changes causing headache, confusion, seizures, and vision loss
- Pyoderma gangrenosum (painful skin ulcers)
- Hepatitis (liver inflammation)
- Thyroiditis (thyroid gland inflammation)
- Thrombotic microangiopathy (TMA) – damage to the smallest blood vessels
Not Known
Frequency cannot be estimated from available data
- Aneurysms and arterial dissections (enlargement, weakening, or tearing of blood vessel walls)
- Hyperammonemic encephalopathy (brain toxicity due to high ammonia levels) – symptoms include lack of energy, confusion, drowsiness, or loss of consciousness
Managing Common Side Effects
Several practical strategies can help manage the most common sunitinib-related side effects. For diarrhea, staying well hydrated, avoiding high-fiber or spicy foods, and using over-the-counter loperamide (after checking with your clinician) are often effective. For hand-foot skin reaction, wearing loose cotton socks and shoes, applying emollient creams (especially those containing urea), avoiding hot water, and reducing mechanical pressure on hands and feet can help. Mouth sores are best managed by maintaining scrupulous oral hygiene, rinsing with bland saline or bicarbonate solutions, and avoiding alcohol-containing mouthwashes. High blood pressure should be checked at home at least twice a week during the first cycle, and any sustained elevation reported to the oncology team.
It is important to report suspected side effects after the medicine has been authorized. This allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals and patients can report suspected adverse reactions to their national pharmacovigilance authority (e.g., the EMA in Europe, the FDA in the United States, or the MHRA in the United Kingdom).
How Should You Store Sunitinib Eugia?
Keep Sunitinib Eugia capsules out of the sight and reach of children at all times. This medication is a potent anticancer agent and accidental ingestion by a child could cause serious harm. Consider using a locked medication cabinet if children are in the household.
There are no special storage conditions required for Sunitinib Eugia. Store in the original packaging to protect from moisture and light. Do not use this medicine after the expiry date (EXP) stated on the carton, bottle, or blister pack. The expiry date refers to the last day of the stated month.
Do not use Sunitinib Eugia if the packaging appears damaged or shows signs of tampering. If you notice any changes in the appearance of the capsules – for example cracked capsule shells, unusual color changes, or loose powder outside a capsule – consult your pharmacist.
Do not dispose of medicines via wastewater or household waste. Return unused or expired capsules to your pharmacy for safe disposal through an approved cytotoxic medication take-back program. These measures help protect the environment and prevent accidental exposure to others, including healthcare workers handling waste.
What Does Sunitinib Eugia Contain?
The active substance in Sunitinib Eugia is sunitinib. Each hard capsule contains either 12.5 mg, 25 mg, 37.5 mg, or 50 mg of sunitinib (as sunitinib malate), with 12.5 mg being the lowest available strength and the starting point for most dose reductions.
Inactive Ingredients
The other ingredients (excipients) are:
- Capsule contents: Microcrystalline cellulose, mannitol (E421), croscarmellose sodium, povidone (E1201), magnesium stearate
- Capsule shell: Gelatin, titanium dioxide (E171), black iron oxide (E172) (higher strengths), red iron oxide (E172), yellow iron oxide (E172)
- Printing ink: Shellac, titanium dioxide (E171), black iron oxide (E172), propylene glycol, ammonium hydroxide
Capsule Identification
| Strength | Capsule Appearance | Typical Size | Imprint |
|---|---|---|---|
| 12.5 mg | Orange cap and orange body | Approximately 14.3 mm | Strength marking (e.g., “12.5 mg”) |
| 25 mg | Light brown cap and orange body | Approximately 15.9 mm | Strength marking (e.g., “25 mg”) |
| 37.5 mg | Yellow cap and yellow body | Approximately 18.0 mm | Strength marking (e.g., “37.5 mg”) |
| 50 mg | Light brown cap and light brown body | Approximately 19.4 mm | Strength marking (e.g., “50 mg”) |
All capsules contain yellow to orange granules. Sunitinib Eugia is typically available in bottles and blister packs of 28 or 30 capsules, including perforated unit-dose blisters (28 × 1 capsules). Not all pack sizes may be marketed in every country. The appearance and imprint details may vary between national markets; always check the carton and patient information leaflet supplied with your medicine.
Marketing Authorization Holder
Sunitinib Eugia is marketed by Eugia Pharma Specialities Ltd., a specialty division of Aurobindo Pharma focusing on oncology and niche injectable/oral formulations. National marketing authorization details, including the local representative and manufacturing sites, are listed in the country-specific Summary of Product Characteristics (SmPC) and patient information leaflet.
Frequently Asked Questions
Sunitinib Eugia is a generic version of SUTENT (the original brand by Pfizer). Both contain the same active ingredient – sunitinib – in the same dosages. Sunitinib Eugia has been demonstrated to be bioequivalent to SUTENT, meaning it is absorbed into the body at the same rate and to the same extent. Regulatory authorities approved Sunitinib Eugia after evaluating its pharmaceutical quality and bioequivalence. Generic medicines typically cost less than the originator brand, which can improve patient access to treatment without compromising clinical efficacy.
The 12.5 mg hard capsule is the lowest available strength of sunitinib. It is essential because dose modifications are performed in 12.5 mg increments. When patients experience significant side effects such as severe hand-foot skin reaction, uncontrolled hypertension, or large drops in blood counts, the clinician typically reduces the dose from 50 mg to 37.5 mg (a combination of 25 mg + 12.5 mg, or two 12.5 mg with one 25 mg, depending on pack availability), and subsequently to 25 mg if needed. The 12.5 mg capsule also represents the lower step of dose reductions for pNET and is commonly used when co-medicating with strong CYP3A4 inhibitors.
Yes, Sunitinib Eugia can be taken with or without food. Food does not significantly affect the absorption of sunitinib. However, you should avoid grapefruit juice and grapefruit products, as they can increase sunitinib levels in your blood and increase the risk of side effects. Swallow the capsules whole with water – do not open, crush, or chew them, as direct contact with the contents can cause skin irritation.
Sunitinib and its active metabolite have a yellow-orange color that can accumulate in the skin, causing a yellowish discoloration. This is a very common side effect and is generally harmless. The discoloration may also affect your hair, making it lighter or changing its color, sometimes in a striking “banded” pattern reflecting the on/off dosing schedule. These changes are typically reversible and resolve after treatment is stopped. Other skin effects such as dryness, hand-foot skin reaction, and changes in pigmentation are also common and should be discussed with your healthcare team so that supportive measures can be offered.
The duration of sunitinib treatment varies depending on the type of cancer, how well the cancer responds, and how well you tolerate the medication. Treatment is typically continued for as long as it is providing benefit and side effects remain manageable. Your doctor will assess your response with regular scans and blood tests. Some patients may take sunitinib for months or even years. Your oncologist will decide when to stop treatment based on disease progression, unacceptable toxicity, or your preferences.
High blood pressure (hypertension) is a very common side effect of sunitinib. Your doctor should check your blood pressure before starting treatment and regularly during treatment. If your blood pressure rises, your doctor may prescribe antihypertensive medication – most commonly an ACE inhibitor, angiotensin receptor blocker, or dihydropyridine calcium-channel blocker. In some cases, a sunitinib dose reduction or temporary treatment interruption may be needed. Do not stop taking sunitinib without consulting your doctor. Regular home blood pressure monitoring is often recommended so that changes can be detected between clinic visits.
Yes, thyroid dysfunction is a very common side effect of sunitinib treatment. The most frequent thyroid effect is hypothyroidism (underactive thyroid), though some patients develop hyperthyroidism (overactive thyroid) or thyroiditis (inflammation of the thyroid). Your thyroid function (TSH, free T4) should be tested before starting sunitinib and monitored regularly during treatment. Symptoms of hypothyroidism include unusual tiredness, feeling cold, weight gain, constipation, dry skin, and changes in voice. If your thyroid becomes underactive, your doctor will prescribe thyroid hormone replacement therapy (levothyroxine), which is safe, effective, and does not interfere with sunitinib’s anticancer activity.
References
- European Medicines Agency (EMA). Sunitinib – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Last updated 2025.
- Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet. 2006;368(9544):1329-1338.
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007;356(2):115-124.
- Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. New England Journal of Medicine. 2011;364(6):501-513.
- U.S. Food and Drug Administration (FDA). SUTENT (sunitinib malate) – Prescribing Information. Available at: www.fda.gov.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Kidney Cancer, Gastrointestinal Stromal Tumors, Neuroendocrine and Adrenal Tumors. Version 2025.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Renal Cell Carcinoma, Gastrointestinal Stromal Tumours, Neuroendocrine Neoplasms. Available at: www.esmo.org.
- British National Formulary (BNF). Sunitinib Monograph. Joint Formulary Committee. London: BMJ Group and Pharmaceutical Press; 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Supplements. 2013;11(2):172-191.
- Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nature Reviews Disease Primers. 2021;7(1):22.
- Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. JNCI: Journal of the National Cancer Institute. 2011;103(9):763-773.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in oncology, hematology, and clinical pharmacology.
Medical Content
iMedic Oncology Editorial Team – specialist physicians in medical oncology with clinical experience in targeted cancer therapy and tyrosine kinase inhibitors
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, NCCN, and ESMO guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.